Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock Portfolio News / By admin April 24, 2019
Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback Portfolio News / By admin April 22, 2019
Gritstone Oncology Announces Proposed Public Offering of Common Stock Portfolio News / By admin April 22, 2019
Surrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer Portfolio News / By admin April 11, 2019